Founded:
2006
Headquarters:
Cambridge, MA
Description:
Genocea develops key breakthroughs in human vaccine discovery and development for antigens that induce T cell immunity.
Founders:
Kevin Bitterman, David Sinclair
Categories:
Biotechnology
Website:
http://www.genocea.com

Detailed Description

Update

Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. The platform, which dramatically reduces the time to discover vaccine candidates, uniquely employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations. Genocea has demonstrated preclinical proof-of-concept with vaccines for herpes simplex virus type 2 (HSV-2), Streptococcus pneumoniae, and Chlamydia trachomatis, infections that affect hundreds of millions of people worldwide. The company expects to begin clinical trials for its lead program, a therapeutic vaccine for HSV-2, in early 2011.

Current Team (11)

Update

Past Team (3)

Update

Board Members and Advisors (7)

Update

Investors (10)

Update

Offices/Locations (2)

Update
  • Headquarters

    100 Acorn Park Drive

    Cambridge, MA 02140

    USA

  • Office

    161 First St.

    Suite 2C

    Cambridge, MA 02142

    USA

Images (1)

Update
  • Akbjazwnziepxmlwc13c